In this study, we demonstrate an improvement in survival with the addition of PD-1 blockade to chemotherapy administered every 2 weeks in a solely PD-L1-positive population with advanced ESCC. The gene discussed is PDCD1; the disease is esophageal squamous cell carcinoma.